Aurinia Pharmaceuticals (AUPH) 6 Aug 212021 Q2 Earnings call transcript

Hello and welcome to the Aurinia Pharmaceuticals' Second Quarter Earnings Call and Webcast. At this time, all participants are in a listen-only mode. [Operator Instructions] A question-and-answer session will follow the formal presentation.

As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Glenn Schulman, Head of Investor Relations. ahead. go Please,

thanks we and for us joining Thanks, Aurinia's to Second as discuss Quarter today Kevin, all Financial Results.

the Joe Financial here at Joining President Neil Solomons, Chief on call Medical are and afternoon me Officer Chief Peter Commercial and Officer; CEO; Max Miller, Officer; Chief Aurinia. our our Colao, our this Greenleaf,

remarks more our X-K note regulatory here Peter, detail as agenda Please today: accessible filed on Peter that significant These at and a in of and current on www.auriniapharma.com. actual questions. SEC Form and course XX-Q. release then the after discussion From report for our and date, during statements available financial launch the afternoon will our whole for financial will some we the also this Note statements be analysis quarterly SEDAR rest on of are we discuss closing and been Our number recent forward-looking performance It's our our a subject outlook results accompanying will Management's are and year Form our to expectations. differ our the ongoing there, risks forward-looking today's statements and this materially. may highlights of press call, and make the with Joe announcing from team uncertainties with and and may website in financial based filed well, our of along LUPKYNIS your that the activities. provide a clinical and for our results operational review

time. refer of Canadian in quarterly press future all website and along affect authorities financial release of and Also discussion the note our of recent Form results on all are to and Security report available and required current filed XX-Q of assume are obligation and could to our a our that With recently For our upon XX-K, call publicly all law, date. please turn our during that, me as with Except business, CEO to XXXX today SEC in that as Peter? now U.S., disclosure statements this as made X, to the such which and based over filings. our available factors call we of by the Peter, let statements this currently at information August the and any today, President. update of no us

Glenn, thanks, want I thank joining this and for us Hey, to afternoon. everybody

we've major you all and So, through today, company strategy. achieved our areas the and four to results with of of going against details to-date. focus through aspects XXXX, the for of walk execution on made first our progress half you Aurinia And significant we're provide

lupus and The at U.S. this the active far treatment by first of of the nephritis. most patients at is with for our LUPKYNIS launch important stage the progress

on touch of to briefly as through all are runway and with filings all our will We access you our on with you to the what Aurinia open company on to and expand may then will update we living includes From will provide walk patients continued to doing we we the and LUPKYNIS, where global an microphone see which end generating the by operationally regulatory and work you data position you this, financial up a we'll for After questions see lastly, strategically have. XXXX. new there, LN. focus our

with and healthcare up data months the of to continue launch. understanding over lupus a that just So, say of and the summer nephritis LUPKYNIS to market supplement the well With our entered our to to characteristics research five guess patient of into I two remains points that just we now attitudes lot quarters into professional undiminished. and the prelaunch under point more confidence this real-world ongoing we're here learn and have behaviors. including we are, and we generated this actually commercial LUPKYNIS environment needless availability,

primary Let's second written XXX. from start this to were key the the a That's generating patients. up start first signal There for with of the We equates approximately metric prescriptions quarter, adoption as for LUPKYNIS. the see LUPKYNIS patient being of a forms, reminder, momentum in XX% clear which quarter. as

generic you physicians As all have used used been that treatments outset. XX know, for the to We've are if disease. last is treat medications to the majority, XX not a the lupus by the nephritis said rare of from disease The unapproved years. that

and date products happy So, are time, have to promotional known prior new you to having and new our the efforts of treatment adoption patients treatment regimens approaches that impact. are healthcare real tell professionals and historically. takes I'm and all Education data but

with me revenue for quarter through the walk here the the $X.X a of expected QX, provide new indication of expectations the the quarter context FDA-approved that in exceeded have significant have and positive because wins not our this believe result. we some prevailing is environment let the performance an combination type shows in Next, and COVID we there with and as In We number did generated net ramp sales. an you for historically This drug consensus message treatment. well. a million is

other some Okay, let's move trends. on positive to

the from patient and patients reported of what north to-date on increase conversion As of last therapy of today, to continues to our XXX well at end we QX. are rate start forms

XX currently at To LUPKYNIS to United lives we behind clinical the the On policies. continuing of that and is number, published payer are million some added coverage. are, in LUPKYNIS covered further States coverage over granularity there pursue provide for coverage today, XXX least front, as

remainder the requirements insert originally prior the had what in-line are package are in are very fact, All restrictions we with policies onerous less much than these Importantly, and therapy expected. authorization our across the optimistic. up will to starting drive of We to reasons to overall the be drive XXXX believe rates. trend and continue down conversion grow time and for our this

prescription it early far, in on to of the our report exceeding acted in-market launch, In compliance on of addition, and is the date results, experienced is these rate so of also rate key low some so been that learnings. has pandemic. abandonment In is I the albeit of expectation. prominent far challenges also and launch initial The face these most many course the we our also of have can

used are on you patients down, you've Almost are types lupus think the of postponing and but I impact the XX% no how heard particular nephritis, with impact I'm all is of the patients before or is look diagnostic has conditions, all problematic. Now, kidney for tell down of either you to COVID matter lupus canceling exited on here in care to treatments been while diagnosed compared patients patients XXXX, which completely Treatment by nephritis that metric XX% patients pandemic. system LN the biopsies healthcare which at. lupus

of lupus a reduced population as addressable by the for extent nephritis was just material we were patients So, use. approved

pandemic-related which identify [ph] over Of have regardless, healthcare also steps LUPKYNIS can by to hopefully up. pre-pandemic refer And are the recede we drive been course, this impeded rate patients rapidly ramp more initial initially that access time. to levels definitive adoption. back to help implemented things the But and factors have and impacts more being today will and proactive

live external regions. reported calls we implication patients. an to, early medical first effort us XX% all and is have vaccinated. nearly LUPKYNIS intent and Aurinia powerful level that date. The healthcare to important market is to with professionals treat has in all The on affairs I'm were on research XX,XXX due that that a This the ease, And has report will of of sales, together more to physician gaining greater stand also quarter is to that high team which The west we as vaccination of efficacy restrictions target for our more The also the and healthcare of percentage versus from efforts, clinicians message field taking in and increased recall. in visit begin than the Our been have is communicate continue especially can team increase. out we is northeast seen calls this force Through to favorably COVID noticeable the access of impact message result. and clients to prescribing glad where of an internal part has these more quarter. last resonating conducted the marketing made with to by professionals the interactions

We and are lupus centers both increased nephrologists. and the rheumatologists community large the both seeing and responses from

entire more, aspire can is Aurinia for more tremendous and you committed only with efforts potential have we been will I lupus urgency nephritis. LUPKYNIS for execute our date patients Knowing our tell of target. remains to the true team While continue we to to to with living that there on realizing do,

think number some revenue shake asked it's upon feel year out. landing. factors to We marketing. mind, with first compliance provide some after would between this steer guidance why the we in early months million on land of and to see net including this reimbursement, still full-year range rate that consensus in how provide So, and the on expected the $XX we current growth million first in and the and a currently want often we conversion like I'm will game. our all improvements, revenue very kindness estimates, Based where will rates, rates, XXXX payer we I forecast our the XX attrition net for the of believe $XX of revenue

in and with make global onto therapy. pleased to Now submitted to shift announce of the I'd approval ex-U.S. treatment that the MAA the We're beyond regulatory nephritis that June, seeking for Voclosporin Europe. active lupus our like in for U.S. to Otsuka our partner the focus our Voclosporin efforts adults

a should of decision be the still expect third that mid-XXXX, With in filed, XXXX. standard an cycle, the we by opinion XX-month quarter made CHAMP anticipated meaning review application around a EMA followed

milestone the financial reminder future encouraging further are strengthen as as payments timeline These in early on EMA with sales to achievement product determined. along alongside as PMDA. for as we, support in tiered and providing result our filing Otsuka the regulatory definitive a earn has as going significantly work to of With all Aurinia, approval to to have for the we well royalties updates Otsuka. in ability JNDA the the to been on is will potential engaged the discussions look Japan, with up Just position to filing of in regards conversations a and forward currently company. This of low to $XX million supplying double-digit revenue additional

continue treatment we for efforts, So globalization XXXX paradigm. drive our objective alongside We in of evolving to as this key our see to new beyond. LUPKYNIS and of data the

of of The XXXX. of to So, May Aurinia achieve end change showing sustained proteinuria team reductions database that analysis study, in supportive treated study were in recap. with no by announced AURORA-X continuation continuation a two-year XXX weeks EGFR that lock LUPKYNIS track past AURORA-X blinded treatment. for we on with at meaningful me let interim This remains the individuals the the

updating therefore of guidance LUPKYNIS. are topline AURORA-X by this calendar critically end with to important the from LN we'll report We We AURORA-X longer-term of be our year. support and believe data treatment will the

to addition Voclosporin and team finalizing the the to protocol working in the initiate AURORA-X, of VOCAL, lupus nephritis. trial is which adolescent In is

in the all As commitments. FDA study with protocol well alignment lactation for is with Voclosporin, our as which a post-marketing

Additional evaluating including novel-dosage formulations are a LUPKYNIS to Phase additional X topical includes of registry team and nephritis and the of that usage Voclosporin initiating oral we also lupus real-world both research applications. work explore is

fund us and excess Now sufficiently execute position need Obviously, one actually With million, how on accomplish? cash to current strategy. in do longer-term to question get to hand remain we moving it of on our we is we enough on capitalized $XXX is the operations financials. to and much important a our have cash what

a business static can year, of change, always course. run things don't we While

immediate no have needs We money. to raise

Something say company that launch. I'm report not position at can a our to early every this of stage in proud

XXXX runway to performance, consistent. into cash highlight Board like some moment remains a Outside earlier take Our recent guidance I'd changes. to of

and appoint of Corporate One continue an the look Business to the and provided and to second Hayden guidance partnering Brenda Balakrishnan her fill to Directors, We experience as initiatives leveraging a Development Aurinia. acquisitions, which on contributions retired at BioMarin, where with to forward Balakrishnan Michael leads Corporate Board we and us Dr. Dr. mergers seat. and Group to long-term President Dr. licensing. Vice the during quarter, our opportunity Strategy, of she is build her

progress strategic right for disease evaluate in focused Finally, business on continues We development. right the on remain identifying through effort out diversifying and the expect remain the objective to We and XXXX. strategy by our long-term autoimmune external to value. committed long-term provide front, the we to stakeholders make an indication key our of assets end pipeline building company on to opportunities with this the

that aspect and LUPKYNIS every know across it the remain and there. to we approach right in So, seeing to place we opportunity the business. sum are team, with confident up, We almost have right a all product get of positive have commercial that we we our trends significant

out, While baton now our I'll Joe the to circle color the I'd to over the of like to end call Miller, to provide things Joe? back on close at CFO, more the pass financials.

afternoon, Thank everyone. and good Peter, you,

June investments XX, and to XX, of equivalents of XXXX, As cash, $XXX.X $XXX million December compared XXXX. Aurinia million had cash at

pipeline supporting revenue operational our into million which $XX,XXX majority current ended for and June commercialization six funding ended $XX,XXX programs, We our of fund post-approval FDA-related R&D June our towards comparison to supply, for corporate post-approval cash the June commercial believe XX, in sufficient $X.X infrastructure of was investments XX, efforts and consideration least is was our we of respectively. cash plans, are cash our funding drug prior-year and XXXX position including and Total investing devoting the our the LUPKYNIS. and three in XX, activities, the $X.X and commitments, revenue commitments Total drug the months XXXX XXXX financial and that commercial and approved at XXXX, million our as Taking period. into the equivalents planned June XX, manufacturing includes resources XXXX. conducting our to months

for the consisted $XXX,XXX adjustments sales January approval of FDA three months and of of Cost six June for $X revenues in of June XX, for and ended XX, following commercial XXXX three million respectively. three ending XX, Our the was revenue, for June months prior sales were This XXXX LUPKYNIS ended period increase $XX.X expenses three to XXXX ended the in XXXX. net of XX, of our were compared the XX%. XXXX $X XXXX. comparison year Cost June primarily and the XX, $XXX,XXX June increased the primarily six June for margin approximately result Gross months $XX.X LUPKYNIS. period. was for to the to sales XXXX SG&A months ended of XX, months and million product

and $XX months six million compared the six following XX, drivers million the and period For the an XXXX, employee-related share-based prior and ended the June in increase to as XX, June related approval. three the were to and to were months XXXX expenses for XX, year support the launch expansion pay benefits of functions and and XXXX ended the June $XX.X The primary SG&A compensation increase of salary, incentive LUPKYNIS of respectively. FDA commercial expense administrative

R&D there was and fees addition, professional such million XXXX an assistance marketing-related programs XX, June and market increase months XX, legal, for for activities XXXX research In patient and in $XX.X $XX.X three were as activities. consulting, June recruiting respectively. ended million the costs, expenses other

the increase and was The by distribution employee-related were XX, an in lower costs, trial expenses The six clinical of offset months clinical party the $XX.X the LUPKYNIS. June XXXX. supply expenses of June primary approval in decrease third drivers $XX.X a other cost together and partially ended with decrease following expenses. dollars million R&D XXXX For million respectively. XX, decrease and and were CRO

ended loss a loss XXXX, million compared common or common For $XX reported net $XX.X XX, per million the to as June of or quarter a ended XX, share the share Aurinia per for June of $X.XX XXXX. net $X.XX quarter

$XX.X I million For loss to common per XX, or net closing would loss million With the to some remarks. compared or back a to recorded of as common XXXX, for of hand Peter June the six months per share. share Peter? Aurinia $X.XX net a $XX.X $X.XX over call that, ended like

the look making belief results, for LUPKYNIS the clear have feel the trajectory to over of And forward people and closing, additional our again, Q&A. show for of open free up this picture we this thank We months With questions. providing to to In metrics for to the operator a serious please microphone the the updates to across and now early With a with quarters turn in continuing us join company. are that, launch taking difference in Joe. it to to and board and operator, success come hope the we all I'd thanks, time autoimmune diseases. like So, our you afternoon. positive you to

Thank from question-and-answer question from first [Operator you. Alethia conducting session. Instructions] be Cantor Young a We'll now coming Fitzgerald. Our is today

Your now line is live.

how Alethia. later data them decisions? are questions Hi, the a taking the feedback help for maybe for Emily duration thinking what and there on as any congrats Thank education I'm about on the could helpful two this based are factors solid nephrologist my you are [ph] have to in of you those on potentially on this you're your and Thanks driving rheumatologists is curious, seeing And efforts do treatment. and make drug if year quarter. that prescribe physicians you. think be follow-up, most

you anything if why Well, to anything if on very start, Max jump to Colao missed I'll I and and I thank much. see And don't has he add.

to different data a a of I a I drug. without have that that, is it's to the think, multitude data-driven in first, compound challenge itself. helping think you are get any the prescriptions. One, have factors point you market initial us It to always

have Phase not that think and the to it's able walk important Phase the but develop to and been physician have patient deliver a deliver in to we that that only We also mind. through I specific we've III, through II data

and expectations on a your drug the single the To its trial around so, X identifying cell come trained I importance on guess physician can't up patient question patient being that with to and that's very emphasize our in are dosing. So, probably getting a the biggest right a is AURORA profiling this is identification in clinical patient. in I the do and enough mind if driver reps the helping and to physician patient critical. strong patient extension

proteinuria right, not patients on product treated. the aggressively. looking the not And not that have and there position overall expectation more and learning is over to they're kept our they're that physicians our that's over that's of time out that if even can we disease levels I not if think treated when severe that these in move to their about shows generally but if is with because this do drug worse to but outcomes reduce control it's and that's something just we're death data time are proteinuria

but the X drug, on induction, one-year initial be not physicians are think over the done We've to this was the remember I to major negative control medical produce date going as data is impact by time. of they putting data cuts AURORA patients So important, in mindset because upon throughout function The of at and go for data at maintain with continued it's No through this just kidney the that to patients year. been we've based set. approval well show as EGFR. to proteinuria data our measured on as meetings able and least negative no

it's to on into that state patients early So we get helpful looking to early going launch year those be on as of ones is import our another we and think in for treatment got launch. and very move second year we of the

So on we Max there. be think missed I going anything it's important. to did

think Thank No, hit you've you. I it perfectly.

from from next Justin today is question and Oppenheimer Your Company. coming Kim

now is live. line Your

questions. And the Hi, taking good afternoon. Thanks the congratulations progress. for on

of which additionally, you be a unconverted as compared of, having sort may to to know what level. insight continue of forms, proportion run payer sort do wanted that any proportion course. forms somewhat or challenge of coverage could bit And to start if with have more about their could the be those talk executed those you XX% conversion what a little rate, Just

let on me too, here So start.

initial it launch, any call even disease wouldn't a as challenge. think I rare I

patient and and in initial on initial think a involves off for alone drug prior I hurdle. process paperwork involves cases that some an most a is the getting

to need want you rate we to Max. on over. any Max rate ahead this You or important. that think Go give sort below get on reported But of conversion color XX% plus is you the that

of is get Peter to involved paperwork some highlights little time. there takes bit that access As and a

There work-in So really start forms also need to where have to the be we some prior at process, point and the any may XX% that done. may appeals in be are of time completed. being XX%

The then there are ourselves that that and with benchmarks. in forms of we've cancellation some when seeing we call. low, been So Peter the rate highlighted but is compare is start relatively especially the canceled, as

less to So XX%. our XX% rate with and XX% than cancellation is see we benchmarks

some that's always to think go a it, that's of And in the I work way then rest to treatment. about think process. So patients portion

the see it. great Got It's that from to prior tick-up through number quarter.

I a forms terms shaping be effect on sort The forms. there. there wondering start the of any third thoughts you just and of I'm the flat. seasonal to which at the is somewhat a Just up is in quarter start just looks rate anticipate with summer think

in I in what start the into tell show offices, course what of I rate the on say the the on affect would that's didn't activity color bit you numbers back how July, of we at consistency the those what in looking drug order of we is would patients is and can for a the numbers obviously the of and we're get month, growth the year. I underneath continue summer the drug consistency But can is reported, range progressive the start our where revenue of you little achieve interested I months to year there comment of in coming half that staying both projected through impact physicians say see of prescribing the numbers to those data and patients forms. of early as

it. Okay, how final encouraging on therapy. it question getting patients data got that you're a are therapy just seeing on I maybe the with seems staying

percentage a that net XX,XXX something patient price the we is and of how if that still about should COGS per should wondering expect we think number. Just as

Joe, we're this that happy you and what tell is in our would I I'll even is, or stage. to think I early number cards about branded give Yes, but low

about. something that's think can track feel I good and we

see even to and half, over this in persistency that's a have but watch early prescriptions we are time. drug than XX% on still know the better, stage. have early Patients think starting that to what the year, I be persistency game but can the on early that we the going and that then side our to so also on at we is months are it's rate you continuing really six patients numbers two that and before that under patients good years launch, number in be, and going year a tell a our I ongoing and less even would

that On the tell was I XX,XXX want we all average think I we net we follow. how need our Joe, which you see can are which above, shapes consistent above other to that trend time a or not on is we're good where take projected, said net but we is continue that. going you And as forward. average score are to I or think and again there, I to positive

between saw of if consistent what saw will and the you're margins looking be you inconsistency reason But say the think the quarter would let's QX there quarters might I say, with quarter. I be two this you out in in Yes, forward fluctuations year. QX, slight first on

thanks much so the progress. Okay, and congrats on

Justin. Thanks,

question next from is Our Maury coming from Jefferies. Raycroft today

Your now line live. is

Farzeen is Thank taking for Maury. everyone, you from Hi on this our [ph] questions.

about clarify, BD to plan. just So the

So proteinuric plans to have kidney explore indications I and plans sort in timing of for other do have asset that you LUPKYNIS to in-license you those.

around was our muffled on its question debt loop kindness in both our, intention the and and the So I [indiscernible] invest DB team exploration little probably line find our and just of we don't said how work our necessarily drive kicked our calls, a that, further that, how and If much diseases. can and area in our LUPKYNIS revolves property. to probably based ability plans would to their is continue we more and is reason registration external to kidney this our of LN. do, plans ways so to we my say it's and previous there. understanding, in external, inability further first view of base intellectual to much further might longevity, further second would extend that would And broad upon into have we not then then change mechanistic, intent any for We go other And be work work. through to that the development

around so. to and what when we formulation to in the We At other have around to diversifying more around totally I which something administer call. report work, meaningful some some ways development do said is are of intellectual we and element center doing would there the of enough other say them our the centered some product property elements both business maybe portfolio is have

goal Our that start XXXX. make is to front on making inroads in

So expect hear us soon more there. from to

has more patients One Great. question prescribed diagnosed newly look LN has yet. I is know been

would even has tougher prescribed the call treat I the it I'll here, As of the patients. which patients to first and and would are probably a earlier repeat majority we said, later is I and product meaning bit on we steroids been tougher we're stage of our, so the seen are MMF treat patients what launched across, the the expected the drug. patient But typing say say continuum, to getting right little we was now our when patients exactly have that and stage

range our time for of down product. change be over positioning. patients. in goal which treatment to is and our How move broad Our goal over time position doesn't a it the to is studied, further But paradigm. was further going We the

much. Yes, thank you so

Thanks.

Our today next Company. Cacciatore question Cowen coming is from Ken from &

now is line live. Your

Hey, as well. on Peter congratulations the all progress and team, here

the you there deeper getting doing indicated. the population real on size And into out are as is, patient the one we're of wondering, launch, time the you and Just still. work a often as handle more of good as we have you asked survey that do indicated, we're questions

you then, you bit just to have Thanks more to this wedded clinicians clinician the clinician amongst anything to the to kinds in of try the So much. so help, socialize market and to talk wondering wants feedback kind and previous each coming have they've surprising leaders. that that key interaction? wondering front opinion products back other and and of this your the facilitate that general you're of as using to more patient, group doing a size getting of that we little talk to to been view interactions sense a you of from here of what kind clinician on Can when about

good and Ken thanks Yes, questions.

So patient But provide population we've consistent what I drill the think I'll EuroChem it will from start. a said stay down. on bit with more the of a little

and think of replicated terms is that patients somewhere, estimates we've the diagnosed can we number that of overarching think population have. what the are through past, in course, patient XX,XXX be that outside XXX,XXX and these the US of Europe US the work we in probably said probably to In there little we and sort Japan

patient sizable population. a it's So

is a to go their disease what are have continuum in patients caveat sort therapy lupus that disease Now drug active there have of down you disease whether nephritis number severity the whether with on what they that they down. in of stage further where there as and of

patients. tendency, and hesitate because patients a who put more probably the question, at of it physicians detail and comfort have more there end. back we'll longer to in for therapies and second little the of which data to in MMF say we I think FDA-approved therapies to in is learning. be has much it to your rheumatologists who feels been same which the have are more new It a today to of smaller likely disease, rheumatology the want that, have of into physicians wide to educate we're like been I around exact be little these getting nephrologists then are question to rare call lower a to of driven physicians on certain decades a patients. a was still disease, continue how seeing least a even not and and get steroids to studied are patients diagnosed And a it, earlier probably we're proteinuria. hasn't down newly not going thing of earnings provide there as point adoption more was, because today on I and like as Eventually think an bit put is diseases aggressive as where the aggressive for have everybody they it into that much going treatment little, where rare past what number with to that course wedded we're new onslaught this as hunting and those seen range lupus on that which what on, are grow our to a grow what you a Which been medicines in they've would leads be So in previous done. press knows, But new that's have would to used try where active the on been treat more, maybe to to the most takes into areas there I do purposeful for innovation aggressive of and our pretty too, learn supports that I think lot we're that paradigm, more therapies we the new to to to gain terms sort innovation. to it's the pertains kidney curve nephritis we commentary

that is train our and representatives. we're early about doing we're in go we're as clinical possible, overly how to we it educating we messaging, our as trying driving what are So

We are and move continually at our we driven working just data. data hard science medical peer to the We're field trying and in forward, not the major to and conferences do speaker trying drive leader liaisons produce to with We're data both peer continue the programs. we're with but programs. new medical trying have, to to thought

it's the So those continuum the for with the say fresh of you treating is I'd would medical this in on tactics education minds us. so physicians, expect

is the involve launch, XX% we when education practitioners consistently within of that just to more see as we them intent than And of their LUPKYNIS would healthcare programs pulse month is well color in to I can our to effort little since run around ask the rheumatologists. prescribe prescribe more see add and the peer to as next an surveys next XXX three research or a bit that extent than we've nephrologist that to what to add KOLs. half more of of our in market months. peer than have We And intent or them over

Max. Thanks,

question is Burton. Martin from next from Bloom Our David

is line live. Your now

with congratulations. you and use cyclophosphamide. seeing Couple of afternoon any Good off-label Are questions.

in it's with patients specifics wide I combo that say, that, it's on I conversations know, it not I of it would know but mix, cyclophosphamide don't is, don't in I come probably have our in up such but range has a have that minimal. but if we

treatment And still in patients lower Okay. early going abandonment drug. any sense, will would mentioned the you relatively or In discussions we're And a to is the draw treat get them the this from adoption of of chronic. I be to do with physicians remission. you some

can about mode, a is data, our talk to messaging the patients proteinuric speak it's It's year, from data I David, when the early out years over a importance the sort early in drug we really straight of six and tell talk that time, we'll maintenance positioning and conjunction it the I months too but about from we and data, don't data a tell in around we to you, know centered of good. physicians two about is with of in just our but see will controlling kind more think to play tell Early start data. or

Okay. launch with do versus split. Benlysta what are are And around kind of getting on how what doctors about all of or same time, that LUPKYNIS putting sense with doctors now patients their just Benlysta LUPKYNIS, the is you treat some a patient then,

you at What max one yesterday on. this Max, just that I'm look about to we take to going talking something and one pitches do to of because it Colao it's we're want

Yes, sure.

are in with again patient have some they through of, do also we the of on anecdotal kind of is high Peter So that between what but market hear proteinuria top when types we we Benlysta that's out. about our intent actually, the to same due a and patient urgency kind data and is the surveys the bringing really that comes our LUPKYNIS the that sense type may different intent and in trials it's In of and Benlysta MMF apportioning research proteinuria steroids, it's are that the of pulse types be physicians the both where prescribe is mentioned, terms currently. its on level down of patients in rheumatologists quickly prescribe, Is surveys. believe then patient, that for forefront. and position patient again that to and to of different that we thinking in look at with as look around there But to the

Okay.

the something Next and little question that in trajectory added missing forms right now question, I you Is the a second about first it my added the just patient XXX think you've looks quarter QX be of to quarter already XXX here. am a modified like you beyond and the looks math done about had start in I accelerating. or

you're what is you're patients. doing quarter numbers think those quarter over putting I additional in

in to a quarter of XXX of XXX. two, remember for So north we up total had date

can additive different forms It every net as patients we an think you those I more, that one on to So quarter-over-quarter. in assumption try whereas not different. trying growth We net to of patient that's about assume think a that of get upon patients we is to start things going think really price two, possible, conversion Is a it happen into be out it less haven't can you to forward growth quickly that rate. be thinking about end to those That's put about can year be to scenarios our lot on different of can't variability the the been can to then the once to bad medication our certain because the because can growth metrics all because to the happen. and average number David, the that top objective feed add we're forward day. on average guided we've be back a tricky. I forecast. numbers commercial don't get those projected be and forms get the based rate that think we It's like in way quarter start as drive there. We but if

cetera numbers so You to to I appreciate. this give you a year dealing net see still get are year. good often, a we asked mean all I et are how we move lot of we can with there persistency, and average we're non-COVID but idea can wanted we parameters the get the upon around of the that based of because got parameters had, end by probably that

I great. have question I other do Okay, can. one And if

and You those. remitting patients get you steroids. your steroids, right and to now kind mentioned only of has been trial of and other MMF on we by From patient the from at own about trials least defined XX% have target failed MMF XX% see

cut that. is now your to smaller XX% So that target a population or remaining than does XX% right down

patients than is therapies not have That's our to and for want we we Well, those more I is where that and are that want of smaller a there once that just but a the already to patients today sort into often MMF be product obviously seen diagnosed be to are initiating question there the think the that say failing MMF activities of is limits course newly and we're data us and where disease of those and two parts is up my back data mix piece position we where where mind, patient. disease diagnosed patients steroid ending can I pie. that they in there suggests be. then wouldn't we and that where steroid newly

understand really haven't numbers that us we are ourselves given because outpaced is Although still that. to we working

it Okay, me. for thanks. That's

The coming next [indiscernible]. today is question from

is line now live. Your

Great, this thanks quarter. the progress for on and congrats taking my question guys, continued

surveys, of So circling when that prescribe being to some indicated half the are could made. LUPKYNIS, back on you these respondents additional about they plan your prescriptions like any looks provide to but pulse it color

Is during and are mainly when there sense it getting treatment. next patients of patient experiencing the on here urgency instance, a it patients kind occurring, visit. flare happening a For of is or is

color there would any be helpful. So, Thanks.

able is, But it's Yes. bit we materialize improving, think we the prescribing anything when how And surveys how on action. survey variable rents, to back materialize I we're not And to have a I ask takes tick that environment Max getting our me of into a to exact into generally question of tell physician that pulse you Yes, are I a seeing an seeing rapidly actual little here. see quantification and up behavior. that. let it it's I'll add we prescribe being quickly for of into but get of offices seen offices, your think in and we it that I'm i.e. improvement now that essence we have had into actual Max. intent patients do will COVID sure more

on practice. of LN I And is as that total patients a of setting. And the No. the patients physician the as setting X this This think most a rare perspective whole highlighted. in on their in kind have are average Peter in X right in disease of community or may

a So basis a it's patients on basis. not these and daily that even seeing on weekly they're not

prescribe data is how how it's to how digest the as intend large, they're you steroid. most prescribing drives patients highlighted the comes level the the MMF then, So urgency is of when in patient mind and and that opportunity my they're positioning. is digesting with and when thinking And they're the and about at and are next high presents if by and very clearly a that visit proteinuria with clearly

standpoint. So there, is of MMF proteinuria, process, going from top to and through a if a going be with is patient gaining discussion From LUPKYNIS the agreement access there mind present process. the steroid prescribing high the of level they

So that's how kind all it works. of

of practice. Operator, So you patients questions. XX% going the can't more have work really is through it's matter a tie the to of they do as we next month the any this, flow realize

further I'd the time. comments floor any like over to turn back for this Instructions] [Operator closing at

Okay, to And Have have of near look we we've again by us in everybody good the well. updating night, us to for today. you we everyone. I forward future. the a obviously will results again with and work but want to seen date, ahead encouraged more thank joining that, We're

you. That conclude webcast. does Thank and teleconference today's

at this you your disconnect We thank You a today. time day. and participation wonderful your have line may for